XML 60 R46.htm IDEA: XBRL DOCUMENT v3.20.4
Intangible Assets (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Finite-lived intangible assets, net   $ 113,660 $ 113,660 $ 340,976  
2018 Aspire Purchase Agreements [Member]          
Finite-lived intangible assets, net       340,976  
Finite-lived intangible assets, accumulated amortization       1,250,238  
Glioblastoma Multiforme Brain Cancer [Member]          
Asset impairment charges       2,400,000  
IPR&D Drug Technology Platforms [Member]          
Asset impairment charges      
IPR&D Drug Technology Platforms [Member] | Ovarian Cancer [Member]          
Finite-lived intangible assets acquired     13,300,000    
EGEN Inc [Member]          
Asset impairment charges         $ 7,000,000
Goodwill, acquisition     2,000,000    
EGEN Inc [Member] | Purchase Agreement [Member]          
Finite-lived intangible assets acquired     $ 1,600,000    
Finite-lived intangible asset, useful life     7 years    
Amortization expense     $ 227,316 $ 227,316  
Finite-lived intangible assets, net   113,660 113,660    
Finite-lived intangible assets, accumulated amortization   1,477,554 1,477,554    
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer [Member]          
Asset impairment charges $ 2,400,000       $ 9,400,000
Non-cash charge   $ 2,400,000      
EGEN Inc [Member] | IPR&D Drug Technology Platforms [Member]          
Indefinite lived intangible assets     $ 24,200,000